A prospective study of detorubicin in malignant mesothelioma
โ Scribed by Nicolas Colbert; Jean-Michel Vannetzel; Victor Izrael; Michel Schlienger; Bernard Milleron; Francois Blanchon; Dominique Herman; Georges Akoun; Jean Roland; Francois Chatelet; Alain Laugier
- Publisher
- John Wiley and Sons
- Year
- 1985
- Tongue
- English
- Weight
- 480 KB
- Volume
- 56
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## BACKGROUND. Gemcitabine has shown activity in patients with less chemosensitive solid tumors. Phase II screening of novel drugs is an accepted method with which to investigate new therapies in malignant mesothelioma. The European Organization for Research and Treatment of Cancer-Lung Cancer Coo
Background The association of mesothelioma and asbestos exposure is well known, but some data suggest that probably many people are still being exposed to asbestos without knowing it. Methods Between 1993 and 1996, 132 cases (77% males) of histologically conยฎrmed malignant pleural mesothelioma and 2
mainly located within the cell processes but not within perikarya. The findings thus mimicked those of classic, pediatric neuroblastoma~.~ In contrast, dense core or neurosecretory-type granules in SITA resemble those of enterochromaffin (endocrine) cells of the digestive tract. They are aggregated